Skip to content

Released Aug 11, 2025, after the close

10-Q filed Aug 15, 2025, 46 days after period end · 0000950170-25-109388

Q2 2025 · 10-Q
Revenue$21.76M−3.2% vs Q2 2024+7.6% vs Q1 2025
Net Income-$33.46MN/M vs Q2 2024N/M vs Q1 2025
EPS Diluted-$0.09N/M vs Q2 2024N/M vs Q1 2025
Gross Profit$10,628,000+2.4%
Operating Income-$25,697,000N/M
Operating Cash Flowderived-$20,668,000N/M
Free Cash Flowderived-$22,555,000N/M
Margins · derived
Gross margin48.8%+2.7 pt vs Q2 2024
Operating margin-118.1%+16.5 pt vs Q2 2024
Net margin-153.7%+49.5 pt vs Q2 2024

What the release said

The release

Same quarter

MetricQ2 2025Q2 2024Q2 2023Q2 2022
Revenue$21.76M$22.49M$27.67M$18.78M
Net Income-$33.46M-$45.72M-$17.04M-$63.54M
EPS Diluted-$0.09-$0.12-$0.22-$0.82

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Standard Biotools Inc. · CIK 1162194 · Engraved from SEC EDGAR